Table Graph
      published meta-analysis   sensitivity analysis   studies

tocilizumab in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death or ventilationdetailed resultsNCT04310228-FAVI (Zhao), 2020 (REV) 0.28 [0.01; 7.92] 0.28[0.01; 7.92]NCT04310228-FAVI (Zhao), 2020 (REV)10%12NAnot evaluable radiologic improvement (14-day)detailed resultsNCT04310228-FAVI (Zhao), 2020 (REV) 3.13 [0.61; 15.92] 3.13[0.61; 15.92]NCT04310228-FAVI (Zhao), 2020 (REV)10%NAnot evaluable adverse eventsdetailed resultsNCT04310228-FAVI (Zhao), 2020 (REV) 1.67 [0.15; 18.88] 1.67[0.15; 18.88]NCT04310228-FAVI (Zhao), 2020 (REV)10%12NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-11-01 01:33 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 395 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons